Compare Aurobindo Pharma with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN AUROBINDO PHARMA/
LUPIN
 
P/E (TTM) x 16.0 -128.4 - View Chart
P/BV x 3.3 2.9 114.0% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 AUROBINDO PHARMA   LUPIN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
LUPIN
Mar-19
AUROBINDO PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs830986 84.2%   
Low Rs527720 73.2%   
Sales per share (Unadj.) Rs333.9369.5 90.4%  
Earnings per share (Unadj.) Rs40.413.4 301.1%  
Cash flow per share (Unadj.) Rs51.837.4 138.4%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.1303.7 78.1%  
Shares outstanding (eoy) m585.91452.49 129.5%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.02.3 88.0%   
Avg P/E ratio x16.863.6 26.4%  
P/CF ratio (eoy) x13.122.8 57.4%  
Price / Book Value ratio x2.92.8 101.9%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,569386,064 103.0%   
No. of employees `00017.917.7 101.0%   
Total wages/salary Rs m25,84931,513 82.0%   
Avg. sales/employee Rs Th10,956.99,453.8 115.9%   
Avg. wages/employee Rs Th1,447.71,782.0 81.2%   
Avg. net profit/employee Rs Th1,324.3343.0 386.1%   
INCOME DATA
Net Sales Rs m195,636167,182 117.0%  
Other income Rs m1,5533,640 42.7%   
Total revenues Rs m197,189170,822 115.4%   
Gross profit Rs m39,51928,822 137.1%  
Depreciation Rs m6,68010,850 61.6%   
Interest Rs m2,6263,078 85.3%   
Profit before tax Rs m31,76718,534 171.4%   
Minority Interest Rs m27-89 -30.2%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m-881-3,400 25.9%   
Tax Rs m7,2699,017 80.6%   
Profit after tax Rs m23,6456,066 389.8%  
Gross profit margin %20.217.2 117.2%  
Effective tax rate %22.948.7 47.0%   
Net profit margin %12.13.6 333.1%  
BALANCE SHEET DATA
Current assets Rs m153,645138,536 110.9%   
Current liabilities Rs m120,42961,299 196.5%   
Net working cap to sales %17.046.2 36.8%  
Current ratio x1.32.3 56.5%  
Inventory Days Days13584 161.4%  
Debtors Days Days64112 56.6%  
Net fixed assets Rs m103,909127,516 81.5%   
Share capital Rs m586905 64.7%   
"Free" reserves Rs m138,322136,517 101.3%   
Net worth Rs m138,908137,422 101.1%   
Long term debt Rs m1,80066,417 2.7%   
Total assets Rs m264,544279,494 94.7%  
Interest coverage x13.17.0 186.5%   
Debt to equity ratio x00.5 2.7%  
Sales to assets ratio x0.70.6 123.6%   
Return on assets %9.93.3 303.5%  
Return on equity %17.04.4 385.7%  
Return on capital %23.88.9 267.5%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,31659,414 163.8%   
Fx outflow Rs m40,58922,282 182.2%   
Net fx Rs m56,72737,132 152.8%   
CASH FLOW
From Operations Rs m16,22016,660 97.4%  
From Investments Rs m-28,768-32,825 87.6%  
From Financial Activity Rs m19,1917,441 257.9%  
Net Cashflow Rs m6,656-8,724 -76.3%  

Share Holding

Indian Promoters % 54.1 46.6 116.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 31.9 86.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.1 101.0%  
Shareholders   69,601 98,259 70.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Ends 187 Points Higher(Closing)

Indian share markets end on a positive note with the Sensex up by 187 points, while the Nifty closed up by 36 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 7, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS